°¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® : Á¦Ç°º°, »ùÇú°, ¿ëµµº°, ±â¼úº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Infectious Respiratory Disease Diagnostics Market Size, Share & Trends Analysis By Product (Instruments, Services, Consumables), By Sample (Blood, NPS), By Application, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1587458
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,443,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,862,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,700,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è °¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 735¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ½ÃÀåÀº 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 5.3%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ±Ô¸ðÀÇ °¨¼Ò´Â ÁÖ·Î COVID-19 °Ë»ç °¨¼Ò¿¡ ±âÀÎÇÕ´Ï´Ù. ±×·¯³ª COVID-19ÀÇ ¿µÇâÀ» ¹ÞÁö ¾Ê´Â ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº °¨¿°¼º È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ »õ·Ó°í Çõ½ÅÀûÀÎ Á¦Ç°À» µµÀÔÇÏ·Á´Â Á¤ºÎ ¹× ºñ¿µ¸® ´ÜüÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, °áÇÙ ¿¬±¸°³¹ß¿¡ ´ëÇÑ Àü ¼¼°è ÅõÀÚ¾×Àº 9¾ï 1,500¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ¹Ì±¹ Á¤ºÎ´Â 2020³â °áÇÙ ¿¬±¸¿¡ ¾à 4¾ï 1,000¸¸ ´Þ·¯¸¦ ÅõÀÚÇß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Àü ¼¼°è »ê¾÷Àº °áÇÙ, RSV, µ¶°¨ µî °¨¿°¼º È£Èí±âÁúȯÀÇ ¹ßº´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯¿£¿¡ µû¸£¸é Æó·ÅÀº ¸Å³â ¾à 420¸¸ ¸íÀÌ Æó·ÅÀ¸·Î »ç¸ÁÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº °¨¿°º´ Áø´ÜÀ» À§ÇÑ Áø´Ü¾à ¹× ¼Ò¸ðǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ Çõ½ÅÀûÀÎ ±â¼úÀ» °³¹ßÇÏ¿© »ý»ê¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿ÉÅäÀδõ½ºÆ®¸®Áî´Â COVID-19 »çÅ·ΠÀÎÇÑ °Ëü äÃë ŰƮ °ø±Þ ºÎÁ·¿¡ ´ëÀÀÇϱâ À§ÇØ 3D ÇÁ¸°ÆÃ ½Ã½ºÅÛÀ» Ȱ¿ëÇÑ 'InstaSwab'À» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ¸éºÀÀº °ÝÀÚ ¸ð¾çÀ¸·Î Â¥¿©Á® ÀÖ¾î ±âÁ¸ ¸éºÀº¸´Ù ´õ ¸¹Àº ¾×ü¸¦ Èí¼öÇÏ°í ¹æÃâÇÕ´Ï´Ù. °¢ ¾÷üµéÀº Ÿ±ê¿¡ ƯȭµÈ Á¤È®ÇÑ Áø´Ü °á°ú¸¦ ¾ò±â À§ÇØ »õ·Î¿î ±â¼úÀ» Ȱ¿ëÇØ Áø´Ü Á¦Ç°À» ÁøÈ­½Ã۰í ÀÖ½À´Ï´Ù.

2021³â 3¿ù, ij³íÀº µðÁöÅÐ ¿¢½º·¹À̸¦ À§ÇÑ ³»ÀåÇü AEC ¾î½Ã½ºÅϽº °³¹ßÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¿¢½º·¹ÀÌ À̹ÌÁö ¼¾¼­´Â ¿¢½º·¹ÀÌ¿¡ ´ëÀÀÇÏ´Â À̹ÌÁö »ý¼º ¹× ½Ç½Ã°£ °¨Áö¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, 2021³â 5¿ù¿¡´Â ͏®Æ÷´Ï¾Æ ´ëÇÐÀÌ Ä¨ ±â¼úÀ» Ȱ¿ëÇÏ¿© SARS-CoV-2 ¹× ÀÎÇ÷翣ÀÚ A Ç׿øÀÇ Á¸À縦 ½Äº°ÇÏ´Â Ãʹΰ¨¼º ºÐÀÚ °Ë»ç¸¦ °³¹ßÇß½À´Ï´Ù. ¶ÇÇÑ RSV, µ¶°¨, COVID-19 È£Èí±âÁúȯÀ» µ¿½Ã¿¡ Áø´ÜÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º °Ë»çµµ ¿©·¯ ¾÷ü¿¡¼­ Ãâ½ÃÇϰí ÀÖÀ¸¸ç, RT-PCR °Ë»ç´Â COVID-19 Áø´ÜÀÇ Ç¥ÁØÀ¸·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª ºÐÀÚ °Ë»ç¿Í °ü·ÃµÈ ³ôÀº °¡°ÝÀº ÀÌ ½ÃÀåÀ» ÀúÇØÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

µ¿µîÇÑ Á¦Ç°ÀÌ ¾ø´Â °Íµµ °¡°Ý »ó½ÂÀÇ ¿øÀÎÀÔ´Ï´Ù. °¢ ºÐÀÚÁø´Ü Á¦Ç°ÀÇ ¿ëµµ¿¡ µû¶ó °¡°ÝÀÌ ÃµÂ÷¸¸º°ÀÎ °Íµµ ÀÌ ¹®Á¦¸¦ ´õ¿í ½É°¢ÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. ±â¾÷µéÀº °¨¿°¼º È£Èí±âÁúȯ Áø´Ü Á¦Ç°ÀÇ º¸±ÞÀ» ´Ã¸®±â À§ÇØ ½ÅÁ¦Ç° Ãâ½Ã, Á¦ÈÞ µîÀÇ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 8¿ù Thermo Fisher Scientific Inc.´Â TaqPath COVID-19 RNase P Combo Kit¿Í TaqPath COVID-19 Fast PCR Combo Kit¶ó´Â µÎ °¡Áö COVID-19 Áø´Ü Á¦Ç°À» ¹Ì±¹ ½ÃÀå¿¡ Ãâ½ÃÇϱâ À§ÇÑ EUA¸¦ ÃëµæÇÏ¿´½À´Ï´Ù.

°¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå °¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå °¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå : »ùÇà ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå °¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå °¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå °¨¿°¼º È£Èí±âÁúȯ Áø´Ü ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦10Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Infectious Respiratory Disease Diagnostics Market Growth & Trends:

The global infectious respiratory disease diagnostics market size is anticipated to reach USD 73.56 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.3% from 2025 to 2030. The decline in market size is majorly attributed to the decline in COVID-19 testing. However, the market without the impact of COVID-19 is expected to grow over the forecast years. The growth can be attributed to an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & nonprofit organizations to introduce novel & innovative products to address the increasing demand. For instance, the global investment in tuberculosis R&D reached USD 915 million, and around USD 401 million was spent by the U.S. government on TB research in 2020.

During the forecast period, the global industry is expected to be driven by the rising incidence of infectious respiratory disorders, such as tuberculosis, RSV, and influenza. According to the UN, pneumonia affects around 4.2 million people every year. Key players are developing innovative techniques to improve production for meeting the growing demand in diagnostics and consumables for the diagnosis of infectious diseases. For instance, OPT Industries Inc. has introduced InstaSwab by utilizing the 3D printing system to address supply shortages of sample collection kits due to the COVID-19 pandemic. These swabs are made of woven lattices to absorb and release more fluid than conventional swabs. Companies are advancing their diagnosis products by using new techniques to gain target-specific and accurate results.

Canon Inc. announced the development of a built-in AEC assistance for digital X-rays in March 2021. The X-ray image sensor enables users to perform picture production and real-time detection of images corresponding to emitted X-rays. Furthermore, in May 2021, the University of California developed an ultrasensitive molecular test to identify the presence of SARS-CoV-2 and influenza A antigens using chip technology. In addition, companies are also launching multiplex tests for the simultaneous diagnosis of RSV, influenza, and COVID-19 respiratory diseases. RT-PCR tests are considered the gold standard for the diagnosis of COVID-19 in patients. However, high prices associated with molecular tests are one of the major factors impeding this market.

The lack of comparable products is another reason for hiked prices. This problem is further compounded by the significant variations in prices for different applications of each molecular diagnostic product. Companies are adopting strategies, such as new product launches and partnerships, to increase the penetration of infectious respiratory disease diagnostics products. For instance, in August 2021, Thermo Fisher Scientific Inc. received EUA for the introduction of two COVID-19 diagnostic products, TaqPath COVID-19 RNase P Combo Kit and TaqPath COVID-19 Fast PCR Combo Kit, in the U.S. market.

Infectious Respiratory Disease Diagnostics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Infectious Respiratory Disease Diagnostics Market Variables, Trends & Scope

Chapter 4. Infectious Respiratory Disease Diagnostics Market: Product Estimates & Trend Analysis

Chapter 5. Infectious Respiratory Disease Diagnostics Market: Sample Estimates & Trend Analysis

Chapter 6. Infectious Respiratory Disease Diagnostics Market: Technology Estimates & Trend Analysis

Chapter 7. Infectious Respiratory Disease Diagnostics Market: Application Estimates & Trend Analysis

Chapter 8. Infectious Respiratory Disease Diagnostics Market: End Use Estimates & Trend Analysis

Chapter 9. Infectious Respiratory Disease Diagnostics Market: Regional Estimates & Trend Analysis

Chapter 10. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â